Geneseeq Technology
About Geneseeq Technology
Geneseeq Technology Inc. is a research-driven global leader in precision oncology, leveraging cutting-edge next-generation sequencing (NGS) technologies to advance cancer detection, diagnosis, and treatment. The company offers comprehensive genomic profiling services, including pan-cancer panels analyzing over 400 genes and cancer-type-specific panels, to provide physicians with actionable insights for guiding optimal treatment strategies, such as targeted therapy and immunotherapy. Their portfolio also encompasses minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED) solutions, with notable products like CanScan® having received FDA Breakthrough Device Designation and GeneseeqPrime® gaining FDA 510(k) clearance, CE-IVD marking, and NMPA approval across major jurisdictions.
Geneseeq integrates advanced AI and machine learning algorithms into its technology platforms for enhanced data analysis and improved diagnostic capabilities. Examples include their TRANQUIL® system for high-resolution gene copy analysis and Calibrate™ for predicting disease relapse through dynamic monitoring of circulating tumor DNA (ctDNA). They have developed proprietary technologies such as ATG-Seq™ for ultra-deep sequencing with three levels of error correction, significantly improving ctDNA detection sensitivity and specificity by addressing challenges like low ctDNA proportion and background noise. Through extensive collaborations with pharmaceutical and academic partners, and by utilizing a large liquid biopsy multi-omics database, Geneseeq is actively involved in biomarker discovery and translational research, aiming to continuously innovate and improve patient outcomes through personalized cancer care.
Focus Areas
Business Intelligence
| Key Investors | Cowin Capital, Guoxin Capital, Xingye Innovation Capital Management, Lilly Asia Ventures, SoftBank China Venture Capital, China Reform Holdings Corporation |
| Partnerships | Jiangsu Vcare PharmaTech, Zai Lab, Illumina, AstraZeneca, Integrated DNA Technologies (IDT) |
| Technology | Next-Generation Sequencing (NGS) platforms, High-Performance Computing (HPC) data center, Machine Learning algorithms, exclusive genomic databases, proprietary bioinformatics pipeline (GENESIS by GENESEEQ), AI-driven whole-genome sequencing (MERCURY™ Technology, ATG-Seq™ Technology, TRANQUIL®) |
| FDA Clearances | 1 cleared products (estimated) |
What Physicians Need to Know
For physicians, Geneseeq Technology offers actionable genomic insights that can significantly guide personalized treatment strategies, including targeted therapies and immunotherapies, by identifying key oncogenic drivers and resistance mechanisms. The availability of highly sensitive, non-invasive liquid biopsy tests for early detection, MRD monitoring, and tracking treatment response/resistance is particularly valuable, especially in cases where tissue biopsies are challenging or for longitudinal surveillance. The rapid turnaround times and high accuracy of their NGS tests, backed by extensive research and regulatory approvals (e.g., FDA Breakthrough Device Designation for CanScanu00ae, NMPA approval for GeneseeqPrimeu2122), provide reliable data for timely clinical decision-making and potentially improved patient outcomes.
Geneseeq offers both central lab testing services and local testing solutions, which include all-inclusive kits and automated bioinformatics software. This suggests potential for various levels of integration, from sending samples to their CLIA/CAP-certified laboratories to enabling in-house genomic testing capabilities for clinical and research partners. They also engage in collaborations with biopharma and research institutions, indicating opportunities for data sharing and research-focused integrations.
Reviews & Opinions
Videos
News, demos, and interviews about Geneseeq Technology.
Videos load interactively. If none appear, search YouTube for Geneseeq Technology →
Press & Coverage
Frequently Asked Questions
Related Companies
QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]
Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]